Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence | Zendy

Andrea Messori | Zendy; Valeria Fadda | Zendy; Dario Maratea | Zendy; Sabrina Trippoli | Zendy; Roberta Gatto | Zendy; Mauro De Rosa | Zendy; Claudio Marinai | Zendy

Open Access

Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence

Author(s) -

Andrea Messori,

Valeria Fadda,

Dario Maratea,

Sabrina Trippoli,

Roberta Gatto,

Mauro De Rosa,

Claudio Marinai

Publication year - 2014

Publication title -

therapeutic advances in musculoskeletal disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.387

H-Index - 35

eISSN - 1759-7218

pISSN - 1759-720X

DOI - 10.1177/1759720x14554792

Subject(s) - medicine , golimumab , adalimumab , tocilizumab , bioequivalence , rheumatoid arthritis , etanercept , equivalence (formal languages) , odds ratio , meta analysis , mathematics , pharmacokinetics , discrete mathematics

No equivalence analysis has yet been conducted on the effectiveness of biologics in rheumatoid arthritis. Equivalence testing has a specific scientific interest, but can also be useful for deciding whether acquisition tenders are feasible for the pharmacological agents being compared.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research